alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

114TH CONGRESS 

2D SESSION H. R. 4669 

To support the establishment of a Standards Coordinating Body in 

Regenerative Medicine and Advanced Therapies. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 2, 2016 

Mr. FOSTER introduced the following bill; which was referred to the 

Committee on Energy and Commerce 

A BILL 

To support the establishment of a Standards Coordinating 

Body in Regenerative Medicine and Advanced Therapies. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Advancing Standards 

5 in Regenerative Medicine Act’’. 


rfrederick on DSK6VPTVN1PROD with BILLS
2 

•HR 4669 IH

1 SEC. 2. SUPPORT FOR THE ESTABLISHMENT OF A STAND2 ARDS COORDINATING BODY IN REGENERA3 TIVE MEDICINE AND ADVANCED THERAPIES. 

4 Subchapter A of chapter V of the Federal Food, 

5 Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amend6 ed by inserting after section 506F the following: 

7 ‘‘SEC. 506G. COORDINATING BODY IN REGENERATIVE MEDI8 CINE AND ADVANCED THERAPIES. 

9 ‘‘(a) IN GENERAL.—The Secretary, in consultation 

10 with stakeholders, including regenerative medicine product 

11 manufacturers and clinical trial sponsors, contract manu12 facturers, academic institutions, standard setting organi13 zations, the National Institute of Standards and Tech14 nology, and other relevant Federal agencies, as appro15 priate, shall facilitate establishment of a public-private 

16 Standards Coordinating Body in Regenerative Medicine 

17 and Advanced Therapies. 

18 ‘‘(b) FUNCTION OF STANDARDS COORDINATING

19 BODY.—Upon establishment of the Standards Coordi20 nating Body in Regenerative Medicine and Advanced 

21 Therapies under subsection (a), the Secretary shall— 

22 ‘‘(1) identify opportunities for the development 

23 of laboratory regulatory science research and docu24 mentary standards that the Secretary determines 

25 would support the development, evaluation, and re26 view of regenerative medicine products; and 


rfrederick on DSK6VPTVN1PROD with BILLS
3 

•HR 4669 IH

1 ‘‘(2) work with such Standards Coordinating 

2 Body, as appropriate, in the development of stand3 ards described in paragraph (1). 

4 ‘‘(c) GUIDANCE.—The Secretary shall issue guidance, 

5 as appropriate, on how standards may be used in regu6 latory review for regenerative medicine and advanced 

7 therapies. 

8 ‘‘(d) DEFINITION.—For purposes of this section, the 

9 term ‘regenerative medicine and advanced therapies’ in10 cludes cell therapy, gene therapy, gene-modified cell ther11 apy, therapeutic tissue engineering products, and human 

12 cell and tissue products, and combination products using 

13 any such therapies or products. 

14 ‘‘(e) NO ADDITIONAL FUNDS.—The Secretary shall 

15 carry out this section using funds otherwise made avail16 able to the Food and Drug Administration. No additional 

17 funds are authorized to be appropriated to carry out this 

18 section.’’. 

Æ 


rfrederick on DSK6VPTVN1PROD with BILLS
**EXHIBIT 21.1**

 

**SUBSIDIARIES OF LANDMARK BANCORP, INC.**

 

 

The onlysignificant subsidiary of the Company is Landmark National Bank, a nationalbanking association with its main office located in Manhattan, Kansas, and withbranch offices located in Auburn, Dodge City (2), Garden City, Great Bend,Hoisington, LaCrosse, Manhattan, Osage City, Topeka and Wamego, Kansas.  The Company also owns all of the commonsecurities of Landmark Capital Trust I, which was formed to issue trustpreferred securities in a private placement. Additionally, the Company formed Landmark Acquisition Corporation tofacilitate the merger transaction with First Kansas Financial Corporation.

 

1

----
#### The People of the State of Illinois, Plaintiff-Appellee, *v.*Louis Albers, Defendant-Appellant.

(No. 73-25;

Fifth District

June 5, 1974.

Robert E. Farrell, of Mt. Vernon, and Bruce Stratton, of Springfield, both of Office of State Appellate Defender, for appellant.

No brief filed for the People.

Opinion by

Mr. PRESIDING JUSTICE G. MORAN.
#### Watson *v.*The State.

October 11, 1910.

Indictment for murder. Before Judge Rawlings. Emanuel superior court. May 12, 1910.

*Daniel & Smith,*for plaintiff in error.

*H. A. Hall, attorney-general,*and *Alfred Herrington, solicitor-general,*by *Hines & J or dan,*contra.

Atkinson, J.

There was no exception to any ruling rtpon any question of law. The evidence was sufficient to support the verdict. The discretion of the judge in refusing a new trial will not be disturbed.

*Judgment affirmed.*

*All the Justices concur.*
Exhibit 32.1



CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





I, Joshua Ralston, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of
General Enterprise Ventures, Inc. for the quarterly period ending June 30, 2019 fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Quarterly Report on Form
10-Q fairly presents in all material respects the financial condition and results of operations of General Enterprise Ventures
Inc.





|Date: April 11, 2023 |  |  | /s/ Joshua Ralston                      | 
|-------------------- |  |  | --------------------------------------- | 
|                     |  |  | Joshua Ralston, Chief Financial Officer |
1 

### Njo, Heather From: Schaeffer, John Sent: Wednesday, December 18, 2013 12:22 PM To: bhinnant@charkit.com Cc: Lewis, Paul; Mattheisen, Mike; Njo, Heather Subject: FW: 127-68-4 Directions for Compliance -- continued Attachments: 98-56-6 Letter of Exemption Sec 4 98-56-6_10162013. pdf; 98-56-6 HPV3 Letter of Intent to Test EPA-HQ-OPPT-2009-0112-0088[1].pdf; HPV3 final rule published.21oct11.pdf
Brian, I was happy to talk with you this morning. If you need additional time to send your response due to t he upcoming holidays, please send me an email with that requestwith the amount of extra time that you think you w ill need. Along with the instructions for submitting an exemption request, I’ve attached some additional documen ts that may be useful or of interest to you (example exemption req uest, example letter­of­intent to test, and a copy of the final rule.) Some quick instructions:

Applying for an Exemption EPA’s Procedures Governing Testing Consent Agreemen ts and Test Rules (40 CFR part 790), provide for ex emptions from test rules (40 CFR part 790, subpart E) only on the basis of data adequacy (i.e., data fulfilling the required testing endpoints is, or will become available, through tes ting under the test rule by another test sponsor). 40 CFR § 790.87. Conditional exemptions are granted to a company tha t agrees to pay fair and equitable reimbursement tothe company upon whose data the granting of my application is b ased. See, 40 CFR § 790.99. Your request, however, is not based on data availability and no other company has agreed t o conduct the testing. An exemption, therefore, is not warranted. An exemption request must contain the following information (see 40 CFR 790.82) a) The identity of the test rule, the chemical iden tity, and the CAS No. of the test substance on whic h the application is based. (b) The specific testing requirement(s) from which an exemption is sought and the basis for the exempt ion request. (c) Name, address, and telephone number of applican t. (d) Name, address, and telephone number of appropri ate individual to contact for further information. (e)(1) If required in the test rule to establish eq uivalence: (i) The chemical identity of the test substance on which the application is based. (ii) Equivalence data specified in § 790.85. (2) If a test rule requires testing of a single rep resentative substance, EPA will consider all forms of the chemical subject to that rule to be equivalent and will not require the submission of equivalence data as described in § 790.85. The exemption request must also contain the stateme nt of agreement of reimbursement (40 CFR 790.99) Hope this helps, enjoy your Holidays. John

John Schaeffer Senior Biologist USEPA/OPPT/CCD/CITB2 1201 Constitution Ave, NW Washington, DC 20460 Mail Code: 7405M Phone: 202­564­8173
# AVS

Quality Management System QPM# A1R-ANM.Q30-F7 Revision 

### 1
Title: Domestic New Action Worksheet with S8 Date: December 17, 2008 

# Record ofContacts 

# 2.0'0-0l/33 FDMSDocket

No_ FAA'- -


## ------ With whom outside theFAA has this proposal been discussed (e.g., ATA, RAA, ALPA, etc.)?

Organizatio"o Person Contacted Date 

### Boeing Sadayoshi Takara 41t4/09

UNCONTROLLED COPY WHEN DOWNLOAIDED Check the Master Us! to Verify Thai This is the Correct Revision Before Use
[Federal Register Volume 69, Number 188 (Wednesday, September 29, 2004)]
[Notices]
[Page 58161]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-21807]


-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[FRL-7821-9]


Gulf of Mexico Program Citizens Advisory Committee Meeting

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the Federal Advisory Committee Act (Public Law 92-463), 
EPA gives notice of a meeting of the Gulf of Mexico Program (GMP) 
Citizens Advisory Committee (CAC).

DATES: The meeting will be held on Tuesday, October 26, 2004, from 8:30 
a.m. to 4:45 p.m.; Wednesday, October 27, 2004, from 10 a.m. to 5 p.m.; 
and Thursday, October 28, 2004, from 8:30 a.m. to 3:30 p.m.

ADDRESSES: The meeting will be held at the Hotel Monteleone, 214 Royal 
Street, New Orleans, LA 70130 (504-523-3341).

FOR FURTHER INFORMATION CONTACT: Gloria D. Car, Designated Federal 
Officer, Gulf of Mexico Program Office, Mail Code EPA/GMPO, Stennis 
Space Center, MS 39529-6000 at (228) 688-2421.

SUPPLEMENTARY INFORMATION: The proposed agenda includes the following 
topics: Election of CAC Officers; participation in GMP Management 
Committee Meeting; participation in Comprehensive Meeting of the GMP 
Focus Teams (Nutrient Enrichment, Habitat, Public Health, Monitoring/
Modeling/Research, Communications).
    The meeting is open to the public.

    Dated: September 22, 2004.
Gloria D. Car,
Designated Federal Officer.
[FR Doc. 04-21807 Filed 9-28-04; 8:45 am]
BILLING CODE 6560-50-M
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Transportation

###### Surface Transportation Board 

          - [STB Finance Docket No. 34541] 

Spokane County, Division of Engineering and Roads (Spokane), a Class III rail carrier, has filed a verified notice of exemption under 49 CFR 1150.41 to acquire from The Burlington Northern and Santa Fe Railway Company (BNSF), a line of railroad known as the Geiger Spur from milepost 1493.95, on its Columbia River Subdivision, to milepost 4.93, on the Geiger Spur, a total distance of 4.93 miles. 

                    This transaction is related to a verified notice of exemption in STB Finance Docket No. 34546,                     *Western Rail Switching, Incorporated—Operation Exemption—Rail Line of Spokane County, WA,*                     wherein Western Rail Switching, Incorporated seeks to operate the line being acquired by Spokane.                 

Spokane certifies that its projected annual revenues as a result of this transaction will not exceed $5 million, and the transaction will not result in the creation of a Class I or Class II rail carrier. 

The transaction was scheduled to be consummated on October 1, 2004. 

                    If the notice contains false or misleading information, the exemption is void                     *ab initio.*                     Petitions to revoke the exemption under 49 U.S.C. 10502(d) may be filed at any time. The filing of a petition to revoke will not automatically stay the transaction.                 

An original and 10 copies of all pleadings, referring to STB Finance Docket No. 34541, must be filed with the Surface Transportation Board, 1925 K Street NW., Washington, DC 20423-0001. In addition, one copy of each pleading must be served on Martin Rollins, Spokane County Prosecuting Attorney's Office, Civil Division, 1115 West Broadway Avenue, Spokane, WA 99260. 

                    Board decisions and notices are available on our Web site at                     *http://www.stb.dot.gov.*

Decided: September 24, 2004.

By the Board, David M. Konschnik, Director, Office of Proceedings. 

Vernon A. Williams, 

Secretary. 

[FR Doc. 04-22340 Filed 10-1-04; 8:45 am] 

BILLING CODE 4915-01-P
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     This  schedule  contains  summary  financial   information  extracted  from
     ULTRONICS CORPORATION  June 30, 1997  financial  statements and
     is qualified in its entirety by reference to such financial statements.
</LEGEND>

<CIK>                         0000894556
<NAME>                        ULTRONICS CORPORATION

       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-31-1997

<PERIOD-END>                                   JUN-30-1997

<CASH>                                                   0
<SECURITIES>                                             0
<RECEIVABLES>                                            0
<ALLOWANCES>                                             0
<INVENTORY>                                              0
<CURRENT-ASSETS>                                         0
<PP&E>                                                   0
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                           0
<CURRENT-LIABILITIES>                                    0
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                             1,000
<OTHER-SE>                                          (1,000)
<TOTAL-LIABILITY-AND-EQUITY>                             0
<SALES>                                                  0
<TOTAL-REVENUES>                                         0
<CGS>                                                    0
<TOTAL-COSTS>                                            0
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                          0
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                      0
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                             0
<EPS-PRIMARY>                                            0
<EPS-DILUTED>                                            0
        


</TABLE>
### §711c. Omitted

#### **Editorial Notes**

#### Codification

Section, Pub. L. 95–195, §5, Nov. 18, 1977, 91 Stat. 1416; Pub. L. 96–88, title V, §509(b), Oct. 17, 1979, 93 Stat. 695, which related to Interim Council to be the acting tribal governing body until tribal officials would be elected, was omitted from the Code as being of special and not general application.
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA F OURTH D ISTRICT

ANDREW STARK , Appellant,

v.

STATE OF FLORIDA , Appellee

.

No. 4D 20

- 2659

[ July 22, 2021 ]

Appeal from the Circuit Court for the Nineteenth Judicial Circuit, St. Lucie County ; Charles A. Schwab

, Judge; L.T. Case No. 562017 CF 003128 A

.
Antony P. Ryan, Regional Counsel, and Richard G. Bartmon

, Assistant Regional Counsel, Office of Criminal Conflict and Civil Regional Counsel, West Palm Beach, for appellant.

Andrew Stark

, Doral

, ap pellant.

No appearance filed for appellee.

P ER C URIAM

.
Affirmed.

W ARNER , G ROSS and A RTAU , JJ., concur

.

* * *

Not final until disposition of timely filed motion for rehearing.
#### § 3284.8 May a unit have multiple operators?

A unit may have only one operator.
Att. 001

Contains Confidential Business Information

Confidential Information Redacted
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration
 By Notice dated May 18, 2004, and published in the 
                    **Federal Register**
                     on June 3, 2004, (69 FR 31412-31413), Abbott Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson Road, Whippany, New Jersey 07981, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed: Drug
ScheduleDihydromorphine (9145)
IHydromorphone (9150)
II
 The company plans to manufacture bulk product and finished dosage units for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Abbott Laboratories to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Abbott Laboratories to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


[FR Doc. 04-21952 Filed 9-29-04; 8:45 am] BILLING CODE 4410-09-M
EXHIBIT 11 – COMPUTATION OF EARNINGS PER SHARE
In thousands of dollars, except per share data           **Three Months Ended March 31,**  **2004** **2003**Numerator:        Net income (loss) $116,460  $71,046 Effect of dilutive securities:        Convertibledebt — 2.625% issued in 1998  —   2,106*LYONS — 1998 issue  —   1,216*Less: Anti-dilutive items  —   (3,322)         Numerator for net loss per common share — diluted $116,460  $71,046 Denominator:        Weighted average common shares  616,557   613,557 Effect of dilutive securities:        Stock options and common stock warrants  3,071   2,960 Convertibledebt — 2.625% issued in 1998  —   8,355*LYONS — 1998 issue  —   3,046*Less: Anti-dilutive items  —   (11,401)         Denominator for net income (loss) per common share — diluted  619,628   616,517 Net income (loss) per common share:        Basic $.19  $.12          Diluted $.19  $.12          
* Denotes items that are anti-dilutive to the calculation of earnings per share.
Exhibit 32.1



                         CERTIFICATION PURSUANT TO
                          18 U.S.C. SECTION 1350,
                          AS ADOPTED PURSUANT TO
               SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the Quarterly Report of Bioethics, Ltd. (the
"Company") on Form 10-QSB for the period ending September 30, 2004 as
filed with the Securities and Exchange Commission on the date hereof (the
"Report"), I, Mark J. Cowan, Chief Executive Officer and Chief Financial
Officer of the Company, certify, pursuant to 18 U.S.C.  1350, as adopted
pursuant to  906 of the Sarbanes-Oxley Act of 2002, that:

          (1) The Report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934; and

          (2) The information contained in the Report fairly presents, in
all material respects, the financial condition and result of operations of
the Company.


  /s/ Mark J. Cowan
    Mark J. Cowan
  Chief Executive Officer and
  Chief Financial Officer

November 9, 2004
Sacramento

River

CCOOLL UUSSAA CCOO

T17N R2W T17N R1W

T16N R2W T16N R1W

35

26

23 24

36

25

31

19

30

2 1

34

27

22

3 6

15 14 13 18

99.3 R

Contract No. 14-06-200-3296A-R-1

Exhibit B

Seaver, Charles W. and Barbara J.

725-202-123

Note: The Public Land Survey depicted here

was digitized from USGS topographic maps.

0 0.5 1

Miles

Date: November 22, 2004

File Name: N:\districts\contracts\seaver_charles_w_and_barbara_j\seaver_charles_w_and_barbara_j.mxd

Contractor's Service Area

Point of Diversion
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsVertical mixing and methane photochemistry in the atmosphere of Uranus: Analysis of Voyager UVS occultation experimentsExtensive capabilities were developed in the analysis of ultraviolet spectrometer (UVS) absorptive lightcurves. The application of these capabilities to the Voyager UVS data sets from Uranus and Neptune has provided significant findings regarding the stratospheres of these planets. In particular, the direct comparison between photochemical models and UVS measurements accomplished by these efforts is unique, and it helps to guarantee that the information returned by the Voyager 2 spacecraft is being used to the fullest extent possible.Document ID19910023728Acquisition SourceLegacy CDMSDocument TypeContractor Report (CR)AuthorsBishop, James*(Michigan Univ. Ann Arbor, MI, United States)*Date AcquiredSeptember 6, 2013Publication DateSeptember 25, 1991Subject CategoryLunar And Planetary ExplorationReport/Patent NumberNASA-CR-188789NAS 1.26:188789Accession Number91N33042Funding Number(s)CONTRACT_GRANT: NAGW-1504Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType19910023728.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024